Posts Tagged ‘Nile Therapeutics (NLTX)’
On May 15, 2012, Nile Therapeutics (NLTX) reported financial results for the first quarter 2012. The company reported grant revenues of $195K in the quarter. Net loss for the quarter was $0.8 million or $0.02 per share. Nile exited the first quarter ended March 31, 2012 with $0.4 million in cash and equivalents. Operating burn for the first three months of 2012 was $0.6 million. (more…)
More on this topic
(What's this?)
Premium: A bunch of treats
(Value Investing, 5/29/12)
Customer Service 2012 – Just Get to the Point
(Venture Chronicles, 5/13/12)
Opposition leader wants House session closed immediately
(The Analytic, 6/4/12)
Napodano: Nile’s Cenderitide Clears Phase 1
On March 26, 2012, Dr. Hsiao D. Lieu, MD, FACC, Nile Therapeutics’ (NLTX) Vice President of Clinical Research, presented the results from the company’s phase 1 safety and pharmacokinetic / pharmacodynamic (PK/PD) clinical trial with cenderitide at the 61th annual Scientific Session of the American College of Cardiology (ACC) meeting held in Chicago, IL. The poster presentation (board #628) was titled, “Initial Experience with Subcutaneous Infusion of Cenderitide in Patients with Chronic Heart Failure.” (more…)
More on this topic
(What's this?)
Finally, knowing your President!
(The Political and Financial Mark..., 5/15/13)
How to Beat the Market
(Gold Stocks Today, 4/25/13)
Early Industry Leaders
(Samurai Trader, 5/13/13)








